A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering
Inflammation expert opinions
Lina Badimon, MD, Barcelona, explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.
Video navigation menu
- Inflammation is an important pathophysiological mechanism in plaque formation/rupture 00:22
- Atherosclerotic plaques reaching inflammatory cells are more susceptible to rupture and produce clinical events 00:43
- CANTOS trial shows that blocking inflammation may have significant clinical benefit 01:32
- Using anti-inflammatory drugs on top of lipid lowering may be a new option for CV prevention 02:35
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
Prof. Lina Badimon is the Director of the Cardiovascular Science Institute (ICCC) in Barcelona in the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
This recording was developed under auspices of PACE-CME. The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Funding to produce this expert opinion was provided by an unrestricted educational grant from Novartis.